Interestingly, an article suggested that PDE5 inhibitors, therapeutic agents for erectile function, may target potential targets of COVID-19 due to their anti-inflammatory, antioxidant, immune response modulating and anti-apoptotic properties [21]. This evidence concerns the gene PDE5A and COVID-19.